RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

about

Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design Nanotechnology: Advancing the translational respiratory research.

P2860

Q37729137-6E7DDC4A-52D9-437B-A14C-5C37BA7AB0C8 Q41105183-64593A08-1812-45D9-BEF1-F811F390363B

P2860

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

Item

http://www.wikidata.org/entity/Q40565908

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

RSV N-nanorings fused to paliv ...... as a nanoparticle RSV vaccine.

@en

type

Item

label

RSV N-nanorings fused to paliv ...... as a nanoparticle RSV vaccine.

@en

prefLabel

RSV N-nanorings fused to paliv ...... as a nanoparticle RSV vaccine.

@en

P1476

RSV N-nanorings fused to paliv ...... as a nanoparticle RSV vaccine

@en

P2093

Charlotte Deloizy

http://www.w3.org/2001/XMLSchema#string

Delphyne Descamps

http://www.w3.org/2001/XMLSchema#string

Jenna Fix

http://www.w3.org/2001/XMLSchema#string

Marie-Anne Rameix-Welti

http://www.w3.org/2001/XMLSchema#string

Sabine Riffault

http://www.w3.org/2001/XMLSchema#string

P2860

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus

Structural basis of respiratory syncytial virus neutralization by motavizumab

Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

Proof of principle for epitope-focused vaccine design

Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.

Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus.

P304

411-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NANO.2016.08.006

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pierre-Louis Hervé

Jason S McLellan

Jean-François Eléouët

P577

2016-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27553073

http://www.w3.org/2001/XMLSchema#string

P921

nanoparticle

P932

5698904

http://www.w3.org/2001/XMLSchema#string

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

about

P2860

P2860

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932